Spire
![SPIRE trials: Bococizumab was insufficiently humanized for long-term use](https://www.pcsk9forum.org/wp-content/uploads/articleplaceholder-150x150.jpg)
SPIRE trials: Bococizumab was insufficiently humanized for long-term use
The development of bococizumab, the third of the PCSK9 monoclonal antibodies, was discontinued by Pfizer in early November (1). Insights from a late breaker trial presentation provide some answers why this might be the case. SPIRE programme: lipid lowering trials The SPIRE program included 6…
read more »![SPIRE-2: Cardiovascular benefit in very high risk patients](https://www.pcsk9forum.org/wp-content/uploads/BarterP-123x150.jpg)
SPIRE-2: Cardiovascular benefit in very high risk patients
Evidence from the two cardiovascular outcomes studies with bococizumab, notably SPIRE-2, added to the buzz around FOURIER. According to PCSK9 Forum Editor Professor Philip Barter (University of New South Wales, Sydney, Australia): ‘Despite follow-up being short due to termination of the development of bococizumab, SPIRE-2…
read more »![Play](https://www.pcsk9forum.org/wp-content/themes/pcsk9forumnew/images/play.png)
![Prof Raul Santos: SPIRE trials with bococizumab](https://img.youtube.com/vi/BwtRWrkCxKI/0.jpg)
Prof Raul Santos: SPIRE trials with bococizumab
The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.
read more »